All of the following are third generation antipsychotics except,

A. Eccentric. Individuals with schizotypal personality disorder (STPD) exhibit odd or eccentric behaviors, speech, and thought patterns. They may dress unusually, speak in vague or metaphorical ways, or hold bizarre beliefs that are not delusional but are far outside societal norms.

B. Mood swings. Frequent mood swings are not a characteristic feature of schizotypal personality disorder. Instead, they are more commonly seen in borderline personality disorder (BPD) or bipolar disorder. While individuals with STPD may experience transient emotional disturbances, their symptoms are more related to social detachment and cognitive distortions than rapid mood fluctuations.

C. Social anxiety. People with STPD experience intense social anxiety, often due to paranoia and distrust of others rather than fear of judgment (as seen in social anxiety disorder). Their discomfort in social situations does not improve with familiarity, leading to persistent isolation.

D. Paranoid. Paranoia is a core symptom of schizotypal personality disorder. Individuals with STPD often have suspiciousness and odd beliefs, such as thinking others are plotting against them or misinterpreting benign events as having hidden meanings. This paranoid thinking contributes to their social withdrawal and difficulty forming close relationships.

A. Haloperidol (Haldol) is a first-generation (typical) antipsychotic that primarily blocks dopamine (D2) receptors. It is associated with a higher risk of extrapyramidal side effects (EPS), including dystonia, akathisia, and tardive dyskinesia, compared to second-generation antipsychotics.

B. Ziprasidone (Geodon) is a second-generation (atypical) antipsychotic that blocks both dopamine (D2) and serotonin (5-HT2A) receptors. It has a lower risk of EPS but can cause QT prolongation, requiring ECG monitoring in patients with cardiac conditions.

C. Risperidone (Risperdal) is a second-generation antipsychotic with dopamine and serotonin antagonism. It is effective for schizophrenia, bipolar disorder, and irritability in autism but has a higher likelihood of prolactin elevation and EPS at higher doses.

D. Olanzapine (Zyprexa) is a second-generation antipsychotic known for its high risk of metabolic side effects, including weight gain, diabetes, and dyslipidemia. It has a lower risk of EPS compared to first-generation antipsychotics.